

MAIA Biotechnology, Inc.
4444 West Lake Street, Suite 1700
Chicago, IL 60606

April 18, 2023

VIA EDGAR & TELECOPY

U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
Washington, D.C. 20549
Attention: Jimmy McNamara

RE: MAIA Biotechnology, Inc. (the “Company”)
Registration Statement on Form S-1 (File No. 333-269606) (the “Registration Statement”)
Request for Acceleration of Effective Date

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), the Company requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement become effective on April 20, 2023 at 5:00 p.m., Eastern Time, or as soon as practicable thereafter, or at such later time as the Company or its counsel may request via telephone call to the staff. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.

Very truly yours,

MAIA Biotechnology, Inc.

By: /s/ Vlad Vitoc
Name: Vlad Vitoc
Title: Chief Executive Officer

cc: Angela Dowd, Esq., Loeb & Loeb LLP